Refractory Glaucoma Treatment Market: Effect and Growth Factors Research and Projection 2018-2026

0

Globally, Glaucoma is on rise. According to the Glaucoma research Foundation, Glaucoma is the leading cause of irreversible blindness globally. Nearly 10% of the glaucoma patients who receive proper treatment still experience a loss of vision. Around 64.3 million people were estimated to be having glaucoma globally in 2013. Furthermore, according to the American Academy of Ophthalmology, the current prevalence is high in Africa, and Latin America. Patients who fail to respond to medications, undergo trabeculectomy surgery. Click TO Read More On Refractory Glaucoma Treatment Market

Refractory Glaucoma Treatment Options

The global refractory glaucoma treatment market can be characterized based on the treatment options and devices available in the market.

Ahmed Glaucoma Valve from New World Medical Inc., is a good treatment option available since 1993 for refractory glaucoma. This device also has applications in primary open angle glaucoma unresponsive to medication, neovascular glaucoma, and congenital or infantile glaucoma. Various studies have reflected the positive outcomes of using Ahmed Glaucoma Valve in refractory glaucoma both in pediatrics and adults. Therefore, this device is in very high demand and usage globally.

Future Market Dynamics

According to the American Academy of Ophthalmology, the global prevalence of glaucoma is estimated to rise to 76 million in 2020 and 111.8 million in 2040. Rapidly aging population will be one of the important factors for the increasing prevalence rate. There would be a disproportionate rise in the prevalence in people residing in Asia and Africa. Slower adoption rate and high cost of the surgery is limiting the market growth of refractory glaucoma treatment devices in emerging nations where cataract surgery is the largely performed eye surgery. With new devices and technology being introduced, there could be a strong wave of growth experienced in the North America and European markets.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/71

Alternate option like CyPass Micro-Stent from Transcend Medical showed impressive results in patients with primary open-angle glaucoma. CyPass is a micro-invasive surgery which according to the FDA guidelines needs to be performed in combination with cataract surgery. This is restricting the wider acceptance among patients due to increased cost.

Clinical trials of Xen System showed positive results with 44% reduction in eye pressure and 65% reduction in IOP medications in one year period. The Xen gel stent form Allergan reduces IOP with a permanent implant that becomes flexible, allowing doctors to use IOP reduction therapies event after the Xen implantation.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Share.

About Author

William Clarke is the lead editor for Oak Tribune. William has written for many publications including the New York Post Vanity Fair and Business Insider. William is based in New York city and covers issues affecting his city and his country. In addition to following the day-to-day life of the Big Apple, William also has a passion rowing and can often be found paddling the shores of NYC.